Pharmacokinetics and Pharmacodynamics of the Glucagon Receptor Antagonist LGD-6972 in a Multi-dose Clinical Trial

被引：0
|
作者：
Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane
Pipkin, J. D.
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1193-P
引用
收藏
页码：A308 / A308
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of the Glucagon Receptor Antagonist LGD-6972
    Vajda, Eric G.
    Plotkin, Diane J.
    Logan, Douglas
    Li, Yong-Xi
    Pipkin, J. D.
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2014, 63 : A290 - A290
  • [2] An Allosteric Glucagon Receptor Antagonist, LGD-6972, Displays Biased Receptor Signaling
    Vajda, Eric G.
    Zhi, Lin
    Marschke, Keith
    DIABETES, 2018, 67
  • [3] Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
    Vajda, Eric G.
    Logan, Douglas
    Lasseter, Kenneth
    Armas, Danielle
    Plotkin, Diane J.
    Pipkin, J. D.
    Li, Yong-Xi
    Zhou, Rong
    Klein, David
    Wei, Xiaoxiong
    Dilzer, Stacy
    Zhi, Lin
    Marschke, Keith B.
    DIABETES OBESITY & METABOLISM, 2017, 19 (01): : 24 - 32
  • [4] Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice
    Vajda, Eric G.
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2013, 62 : A290 - A290
  • [5] LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes
    Vajda, Eric G.
    Potter, Scott C.
    Fujitaki, James M.
    Reddy, Raja K.
    Van Poelje, Paul D.
    Lee, Yong-Hee
    Henderson, Ian
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2012, 61 : A252 - A252
  • [6] Crossover study comparing bioavailability of a capsule formulation of the glucagon receptor antagonist LGD-6972 to an oral solution formulation in healthy subjects
    Pipkin, J. D.
    Vajda, E.
    Biernat, L.
    Klein, D. J.
    Li, Y. -X.
    Zangmeister, M.
    Zhou, R.
    Zhi, L.
    Marschke, K.
    DIABETOLOGIA, 2017, 60 : S399 - S400
  • [7] Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
    Sidharta, P. N.
    Treiber, A.
    Dingemanse, J.
    CLINICAL PHARMACOKINETICS, 2015, 54 (05) : 457 - 471
  • [8] Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
    P. N. Sidharta
    A. Treiber
    J. Dingemanse
    Clinical Pharmacokinetics, 2015, 54 : 457 - 471
  • [9] Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
    Fan, Yaxin
    Li, Yi
    Chen, Yuancheng
    Yu, Jicheng
    Liu, Xiaofen
    Li, Wanzhen
    Guo, Beining
    Li, Xin
    Wang, Jingjing
    Wu, Hailan
    Wang, Yu
    Hu, Jiali
    Guo, Yan
    Hu, Fupin
    Xu, Xiaoyong
    Cao, Guoying
    Wu, Jufang
    Zhang, Yingyuan
    Zhang, Jing
    Wu, Xiaojie
    ANTIBIOTICS-BASEL, 2022, 11 (06):
  • [10] Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin
    Pettus, Jeremy
    Vajda, Eric G.
    Pipkin, James
    Williamson, Gretchen
    Zangmeister, Miriam A.
    Li, Yong-Xi
    Henry, Robert R.
    D'Alessio, David
    Frias, Juan P.
    Zhi, Lin
    Marschke, Keith
    DIABETES, 2018, 67
12345